Market Overview

Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy

Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy
Related PRGO
10 Biggest Price Target Changes For Tuesday
Benzinga's Top Upgrades, Downgrades For November 13, 2018

Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s business has faced multiple pressures, including industry-wide price erosion, a legal battle for possible collusion in generic drug pricing along with a management transition. At the same time, some analysts see the bullish case for owning the stock moving forward.

The Analyst

Argus' Jasper Hellweg upgraded Perrigo's stock from Hold to Buy with a new $93 price target.

The Thesis

Perrigo's status as being a leader in the OTC generic drugs industry remains unchanged and a new management team continues to restructure its operations and shown initial signs of success, Hellweg said in a note. Some of the initiatives the company took include a focus on organic growth, openness to exiting unprofitable units and a focus on paying down debt. The company expects its initiatives to generate more than $130 million in annual savings by the middle of next year, the analyst said.

Perhaps more important, Perrigo's pipeline includes around 20 product candidates that are awaiting approval by the U.S. Food and Drug Administration, the analyst said. As such, the stock is "favorably valued" in the low $80 range which implies a multiple of 17 times on estimated 2017 EPS, which is below its five-year historical average range of 10.1-26.0 and below the peer group average of 18.7 times.

Price Action

Shares of Perrigo gained more than 1 percent ahead of Friday's market open.

Related Links:

RBC: Perrigo's Near-Term Risk Lessens, But Long-Term Issues Persist

Digesting Delivering Alpha 2017: The Top Picks You Need To Know

Latest Ratings for PRGO

Nov 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Nov 2018BerenbergDowngradesBuyHold
Aug 2018Wells FargoMaintainsMarket PerformMarket Perform

View More Analyst Ratings for PRGO
View the Latest Analyst Ratings

Posted-In: Argus Generic drugs Jasper HellwegAnalyst Color Upgrades Price Target Top Stories Analyst Ratings Best of Benzinga


Related Articles (PRGO)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Argus Awaits A Better Entry Point For Thor Industries, Downgrades To Hold

5 Biggest Price Target Changes For Friday